Articles

Association of interleukin-6 rs1800796 polymorphism with keloid susceptibility and severity in a Vietnamese population: a case-control study

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 10 September 2026
20
Views
8
Downloads

Authors

Keloids are fibroproliferative skin tumors characterized by excessive collagen deposition and persistent inflammation. Interleukin (IL)-6 plays a key role in wound healing and fibrosis, and promoter polymorphisms of the IL-6 gene have been implicated in keloid susceptibility in several populations. However, data on Vietnamese patients remain limited. We conducted a case-control study including 47 patients with clinically diagnosed keloids and 43 age- and sex-matched healthy controls to investigate the association between the IL-6 rs1800796 (−572 C>G) polymorphism and both keloid susceptibility and scar severity. Genotyping was performed using allele-specific oligonucleotide – polymerase chain reaction (ASO-PCR). Scar severity was assessed using the Vancouver Scar Scale (VSS). The CG genotype and G allele were significantly more frequent in patients with keloid than in controls. Carriers of the G allele demonstrated an increased risk of keloid formation and exhibited progressively higher VSS scores compared with CC homozygotes. These findings suggest that the IL-6 rs1800796 G allele is associated with increased susceptibility to keloids and greater scar severity in Vietnamese patients.

Downloads

Download data is not yet available.

Citations

1. Chike-Obi CJ, Cole PD, Brissett AE. Keloids: pathogenesis, clinical features, and management. Semin Plast Surg 2009;23:178-84.
2. Knowles A, Glass DA, 2nd. Keloids and Hypertrophic Scars. Dermatol Clin 2023;41:509-17.
3. McGinty S, Siddiqui WJ. Keloid. Treasure Island (FL): StatPearls [Internet]; 2025 [updated 2023 Jul 17]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507899/.
4. Latoni DI, McDaniel DC, Tsao H, Tsao SS. Update on the Pathogenesis of Keloid Formation. JID Innov 2024;4:100299.
5. Wang ZC, Zhao WY, Cao Y, et al. The Roles of Inflammation in Keloid and Hypertrophic Scars. Front Immunol 2020;11:603187.
6. Nangole FW, Agak GW. Keloid pathophysiology: fibroblast or inflammatory disorders? JPRAS Open 2019;22:44-54.
7. Mahmoud NN, Hamad K, Al Shibitini A, et al. Investigating Inflammatory Markers in Wound Healing: Understanding Implications and Identifying Artifacts. ACS Pharmacol Transl Sci 2024;7:18-27.
8. Johnson BZ, Stevenson AW, Prele CM, et al. The Role of IL-6 in Skin Fibrosis and Cutaneous Wound Healing. Biomedicines 2020;8.
9. Ghazizadeh M. Essential role of IL-6 signaling pathway in keloid pathogenesis. J Nippon Med Sch 2007;74:11-22.
10. Ghazizadeh M, Tosa M, Shimizu H, et al. Functional implications of the IL-6 signaling pathway in keloid pathogenesis. J Invest Dermatol 2007;127:98-105.
11. Liu M. Cytokines, chemokines and growth factors involved in keloids pathogenesis. An Bras Dermatol 2025;100:300-7.
12. Liu S, Yang H, Song J, et al. Keloid: Genetic susceptibility and contributions of genetics and epigenetics to its pathogenesis. Exp Dermatol 2022;31:1665-75.
13. Tosa M, Watanabe A, Ghazizadeh M. IL-6 Polymorphism and Susceptibility to Keloid Formation in a Japanese Population. J Invest Dermatol 2016;136:1069-72.
14. Zhu XJ, Li WZ, Li H, et al. Association of interleukin-6 gene polymorphisms and circulating levels with keloid scars in a Chinese Han population. Genet Mol Res 2017;16:gmr16029110.
15. Allah AMKA, Mohammed KI, Farag AGA, et al. Interleukin-6 serum level and gene polymorphism in keloid patients. Cell Mol Biol 2019;65:43-8.
16. Ogawa R. Japan Scar Workshop (JSW) Scar Scale (JSS) for Assessing Keloids and Hypertrophic Scars. In: Teot L, Mustoe TA, Middelkoop E, Gauglitz GG, editors. Textbook on Scar Management: State of the Art Management and Emerging Technologies [Internet]. Springer; 2020. p. 133-40.
17. Sullivan T, Smith J, Kermode J, et al. Rating the burn scar. J Burn Care Rehabil 1990;11:256-60.
18. Dmytrzak A, Lewandowska K, Boron A, et al. No Association of Polymorphisms in the Genes Encoding Interleukin-6 and Interleukin-6 Receptor Subunit Alpha with the Risk of Keloids in Polish Patients. Int J Mol Sci 2024;25:5284.
19. Lee CC, Tsai CH, Chen CH, et al. An updated review of the immunological mechanisms of keloid scars. Front Immunol 2023;14:1117630.
20. Uitto J. IL-6 signaling pathway in keloids: a target for pharmacologic intervention? J Invest Dermatol 2007;127:6-8.

Supporting Agencies

This research was funded by the University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam, under contract number 211/2024/HĐ-ĐHYD, dated August 22, 2024.

How to Cite



1.
Chau NH, Le HT, Huynh PA, Nguyen NNQ, Van TT. Association of interleukin-6 rs1800796 polymorphism with keloid susceptibility and severity in a Vietnamese population: a case-control study. Dermatol Reports [Internet]. 2026 Sep. 10 [cited 2026 Sep. 14];. Available from: https://journals.pagepress.net/dr/article/view/10835